![](/fileadmin/_processed_/csm_Roche3_cd0afd0272.png)
Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...
![](/fileadmin/_processed_/csm_DKFZ_abcda82777.jpg)
Protein flags Car-T cells for digestion by NK cells
The protein B7H6, which is highly expressed on activated human T cells, can flag the cells for clearance by natural killer (NK) cells, weakening the...
![](/fileadmin/_processed_/csm_Electrochea_process_c40cabeed1.png)
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
![](/fileadmin/Content/NewsAndStories/2024/SciRhom_01_2_80_.png)
SciRhom GmbH closes €63m Series A financing
SciRhom GmbH’s Series A financing was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners - new investor...
![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_Long_Covid_2f520d79f7.png)
British PrecisionLife Ltd inks partnership with Metrodora Institute
The Oxford-based Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) expert PrecisionLife Ltd and US-based clinical specialist...